Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1136-1141

  Dasgupta, Tina ^a   Haas Kogan, Daphne A ^a   Yang, Xiaodong ^a   Olow, Aleksandra ^a   Yang, Daniel X ^a   Gragg, Ashley ^a   Orloff, Lisa A ^a   Yom, Sue S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRAF V600E; PLX4032; PLX4720; Radiosensitization; vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CARCINOMA; CELL CYCLE PROGRESSION; CELL VIABILITY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENOTYPE; HUMAN; HUMAN CELL; IC 50; IONIZING RADIATION; MULTIMODALITY CANCER THERAPY; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIZATION; WESTERN BLOTTING; WILD TYPE;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; GENOTYPE; HUMANS; INDOLES; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION TOLERANCE; RADIATION, IONIZING; SULFONAMIDES;

EID: 84884815722     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9928-9     Document Type: Article

References (24)

1. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM (2012) Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades. Oncotarget (9):954-87
2. Gokhale PC, McRae D, Monia BP, Bagg A, Rahman A, Dritschilo A, Kasid U (1999) Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev 9(2):191-201
3. Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16(1):17-44. doi: 10.1677/ERC-08-0154
4. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69(11):4885-4893. doi: 10.1158/0008-5472.CAN-09- 0727
5. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70(2):512-519. doi: 10.1158/0008-5472.CAN-09-1851
6. Xing M (2010) Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321(1):86-93. doi: 10.1016/j.mce.2009.10.012
7. Nucera C, Lawler J, Hodin R, Parangi S (2010) The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget 1(8):751-756
8. Horbinski C, Nikiforova MN, Hagenkord JM, Hamilton RL, Pollack IF (2012) Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 14(6):777-789. doi: 10.1093/neuonc/nos077
9. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-Analysis. PLoS One 7(10):e47054. doi: 10.1371/journal.pone.0047054
10. Kasid U, Dritschilo A (2003) RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 22(37):5876-5884. doi: 10.1038/sj.onc.1206700
11. Nucera C, Goldfarb M, Hodin R, Parangi S (2009) Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 1795(2):152-161. doi: 10.1016/j.bbcan.2009. 01.003
12. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516. doi: 10.1056/NEJMoa1103782
13. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C (2008) BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6(5):751-759. doi: 10.1158/1541-7786.MCR-07-2001
14. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1(5):2315-2319. doi: 10.1038/nprot.2006.339
15. Xing J, Liu R, Xing M, Trink B (2011) The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun 404(4):958-962. doi: 10.1016/j.bbrc.2010.12.088
16. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G (2010) Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 95(1):450-455. doi: 10.1210/jc.2009-0373
17. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol J Eur Soc Ther Radiol Oncol 98(3):394-399. doi: 10.1016/j.radonc.2010.12.017
18. Dasgupta T, Yang X, Hashizume R, Olow A, Kolkowitz I, Weiss W, Mueller S, Nicolaides T, James CD, Haas-Kogan DA (2012) Survival advantage with radiation combined with a selective BRAF V600E inhibitor in an orthotopic, intracranial model of BRAF V600E-mutated high-grade gliomas. Int J Radiat Oncol Biol Phys 84(3):S125
19. Dasgupta T, Yom SS, Yang X, Sottero T, Nicolaides TP, James CD, Haas-Kogan DA (2010) B-Raf inhibitor PLX4720 enhances the activity of temozolamide and radiation in a human glioblastoma cell line. Int J Radiat Oncol Biol Phys 78(3):S169, abstract number 2992
20. Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res Off J Am Assoc Cancer Res 17(24):7595-7604. doi: 10.1158/1078-0432.CCR-11-1456
21. Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA (2011) Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett 306(2):223-229. doi: 10.1016/j.canlet.2011. 03.010
22. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93(11):4331-4341. doi: 10.1210/jc.2008-1102
23. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358-365. doi: 10.1016/S0140-6736(12)60868-X
24. Flaherty KT (2012) Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clin Exp Metastasis 29(7):841-846. doi: 10.1007/s10585-012-9488-y